Your browser doesn't support javascript.
loading
Endometrial Carcinoma: Specific Targeted Pathways.
Eritja, Nuria; Yeramian, Andree; Chen, Bo-Juen; Llobet-Navas, David; Ortega, Eugenia; Colas, Eva; Abal, Miguel; Dolcet, Xavier; Reventos, Jaume; Matias-Guiu, Xavier.
Affiliation
  • Eritja N; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Yeramian A; GEICEN Research Group, Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Chen BJ; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Llobet-Navas D; GEICEN Research Group, Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Ortega E; New York Genome Center, New York, NY, 10013, USA.
  • Colas E; Institute of Genetic Medicine, Newcastle University, Newcastle-Upon-Tyne, NE1 3BZ, UK.
  • Abal M; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Dolcet X; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Reventos J; GEICEN Research Group, Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Av Rovira Roure, 80, 25198, Lleida, Spain.
  • Matias-Guiu X; Research Unit in Biomedicine and Translational and Pediatric Oncology, Vall d'Hebron Research Institute, Barcelona, Spain.
Adv Exp Med Biol ; 943: 149-207, 2017.
Article in En | MEDLINE | ID: mdl-27910068
ABSTRACT
Endometrial cancer (EC) is the most common gynecologic malignancy in the western world with more than 280,000 cases per year worldwide. Prognosis for EC at early stages, when primary surgical resection is the most common initial treatment, is excellent. Five-year survival rate is around 70 %.Several molecular alterations have been described in the different types of EC. They occur in genes involved in important signaling pathways. In this chapter, we will review the most relevant altered pathways in EC, including PI3K/AKT/mTOR, RAS-RAF-MEK-ERK, Tyrosine kinase, WNT/ß-Catenin, cell cycle, and TGF-ß signaling pathways. At the end of the chapter, the most significant clinical trials will be briefly discussed.This information is important to identify specific targets for therapy.
Subject(s)
Key words
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Endometrial Neoplasms / Molecular Targeted Therapy / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Adv Exp Med Biol Year: 2017 Document type: Article Affiliation country:
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Endometrial Neoplasms / Molecular Targeted Therapy / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Adv Exp Med Biol Year: 2017 Document type: Article Affiliation country: